Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine vs Lifitegrast for Post-PRK Ocular Symptoms
NCT06624384Phase 1Not yet recruiting
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of cyclosporine 2% ophthalmic solution and lifitegrast in ocular inflammation (3 arms). Primary endpoint: Average eye inflammatory symptoms at 1 week. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
cyclosporine 2% ophthalmic solutionlifitegrast
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT06624384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06624384.